相关实验视频

Updated: Jul 2, 2025

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

TEP RNA:为NSCLC的早期诊断提供了一个新的前沿

Yuan Wang^1,2, Aiping Dong¹, Minhan Jin^1,2

¹Clinical Laboratory, The First Affiliated Hospital of Weifang Medical University (Weifang People's Hospital), Weifang Medical University, Weifang, 261000, Shandong, China.

Journal of cancer research and clinical oncology

|February 19, 2024

概括

血小板衍生RNA显示为早期非小细胞肺癌 (NSCLC) 检测的液体活检生物标志物具有前途. 进一步的研究对于完善诊断准确性和整合这些标记物至关重要,以改善肺癌查和预后.

科学领域:

在瘤学瘤学.
分子诊断学分子诊断学
生物标志物发现发现

背景情况:

非小细胞肺癌 (NSCLC) 是癌症死亡的主要原因.
液体活检 (LB) 为癌症诊断提供了一种微创的替代组织活检.
目前用于早期肺癌检测的LB方法需要改进,需要识别新的生物标志物.

研究的目的:

探索血小板衍生RNA (TEP RNA) 作为NSCLC诊断的预测性液体活检生物标志物的潜力.
审查血小板在NSCLC瘤发生,发育和转移中的作用.
总结TEP RNA在NSCLC中的诊断,预后和治疗价值.

主要方法:

关于血小板生物学及其与瘤相互作用的文献综述.
对研究NSCLC中TEPRNA的研究进行分析.
讨论检测TEP RNA的方法.

主要成果:

在NSCLC患者和健康个体之间存在TEP RNA表达的显著差异.
血小板在NSCLC的进展和转移中发挥着至关重要的作用.
TEP RNA 具有 NSCLC 诊断和预后的潜力.

结论:

对NSCLC的基于血小板的诊断方法处于早期发展阶段.
TEP RNA-seq需要进一步验证,以确保在不同人群中诊断的准确性.
将TEP RNA标记物与其他生物标记物的整合可以提高NSCLC查,监测和预后.

关键词:

生物标志物生物标志物诊断诊断诊断诊断诊断非小细胞肺癌的肺癌.在 TEP RNA 中.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...